Solid Biosciences (SLDB) Other Accumulated Expenses (2017 - 2024)

Solid Biosciences has reported Other Accumulated Expenses for 7 years, with the latest figure at $92000.0 in Q1 2024.

• Quarterly Other Accumulated Expenses rose 67.27% year-over-year to $92000.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $92000.0 (up 67.27% YoY) and the FY2023 annual result came in at $24000.0, up 71.43% from the prior year.
• Other Accumulated Expenses improved to $92000.0 in Q1 2024 per SLDB's latest filing, from $24000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $162000.0 in Q3 2023 and troughed at $14000.0 in Q4 2022.
• A 4-year average of $74250.0 and a median of $67000.0 in 2021 frame the typical range for Other Accumulated Expenses.
• The widest YoY moves for Other Accumulated Expenses: up 408.7% in 2023, down 63.33% in 2023.
• Over 4 years, Other Accumulated Expenses stood at $35000.0 in 2021, then slumped by 60.0% to $14000.0 in 2022, then soared by 71.43% to $24000.0 in 2023, then soared by 283.33% to $92000.0 in 2024.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $92000.0, $24000.0, and $162000.0 for Q1 2024, Q4 2023, and Q3 2023 respectively.